New schizophrenia drug emraclidine enters Mid-Stage trial

NCT ID NCT07145918

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests an investigational drug called emraclidine in about 268 adults with schizophrenia. The trial has two parts: Part A looks at how the drug moves through the body and its safety at different doses, while Part B measures whether it improves symptoms like hallucinations and delusions compared to a placebo. Participants take either emraclidine or placebo tablets for up to 42 days and are followed for 30 days after the last dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emraclidine
What this could lead to: If this trial succeeds, it could point toward a new treatment option for schizophrenia that helps control symptoms with a different mechanism than current drugs.
What could go wrong: This is an early Phase 2 study with a small number of participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

California Clinical Trials Medical Group - Parexel /ID# 275751
RECRUITING

Glendale, California, 91206, United States
Cbh Health - Gaithersburg /ID# 272932
RECRUITING

Gaithersburg, Maryland, 20877, United States
Cenexel Hassman Research Institute (Hri) /ID# 276128
RECRUITING

Marlton, New Jersey, 08053, United States
Collaborative Neuroscience Research - Garden Grove /ID# 273005
RECRUITING

Garden Grove, California, 92845, United States
Community Clinical Research - Austin - Cross Park Drive /ID# 272977
RECRUITING

Austin, Texas, 78754, United States
Pillar Clinical Research - Richardson /ID# 275715
RECRUITING

Richardson, Texas, 75080, United States
Woodland International Research Group /ID# 275747
RECRUITING

Little Rock, Arkansas, 72211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.